Parkinson disease (PD) progression centers on α-synuclein (SNCA) misfolding + aggregation in dopaminergic neurons. Step 1: α-synuclein expression — physiological role at presynaptic terminals (vesicle trafficking via SNARE-complex assembly). Step 2: misfolding — exposure to oxidative stress (rotenone, MPTP), mitochondrial dysfunction (complex I deficit), or genetic forms (SNCA point mutations A53T/A30P/E46K + duplications/triplications) → β-sheet conformer. Step 3: aggregation kinetics — monomer → oligomers (most toxic) → protofibrils → mature fibrils → Lewy bodies + Lewy neurites (the histopathologic signature). Step 4: prion-like spread — misfolded α-synuclein templates further misfolding cell-to-cell; staging via Braak hypothesis follows the olfactory bulb → brainstem → midbrain → cortex axis. Step 5: dopaminergic neurodegeneration — substantia nigra pars compacta loss → striatal DA depletion → motor symptoms (bradykinesia, rigidity, resting tremor) emerge at ~50-70% DA neuron loss. Step 6: cellular stress amplification — α-synuclein oligomers disrupt mitochondria, ER homeostasis (UPR — cross-link upr er stress perk ire1 atf6), lysosomes (CMA failure), and trigger microglial activation. Step 7: non-motor progression — autonomic dysfunction, REM sleep behavior disorder (often pre-motor), cognitive decline (PDD). Genetics: SNCA, LRRK2 (most common autosomal dominant), GBA (lysosomal — strongest single risk factor), PRKN/PINK1/DJ-1 (autosomal recessive — mitophagy defects). Therapeutics: levodopa + carbidopa — symptomatic gold standard; MAO-B inhibitors (selegiline, rasagiline) — DA preservation + possible neuroprotection; dopamine agonists; COMT inhibitors; deep brain stimulation. Disease-modifying programs in development (anti-α-synuclein mAbs, LRRK2 inhibitors, GBA gene therapy). Cross-links: catecholamine synthesis (DA depletion), mitochondrial peptide signaling (complex I + mitophagy), autophagy lc3 axis (lysosomal failure), neuroinflammation microglia priming.
Organ Systems
nervous
Pathway Steps
α-synuclein (physiological) → misfolded β-sheet conformer — via oxidative stress + mitochondrial dysfunction + genetic mutation (A53T, A30P, E46K). α-Synuclein is normally a soluble presynaptic protein involved in vesicle trafficking. In disease it misfolds from its native state into a β-sheet-rich conformer — the seed of aggregation. Gene multiplication (more protein) and point mutations (faster misfolding) both cause familial Parkinson’s, supporting a causal role.
misfolded α-synuclein → soluble oligomers (most toxic species) — via concentration-driven aggregation; oligomers > fibrils for cellular toxicity. Misfolded monomers assemble first into soluble oligomers, now considered the most toxic species — more so than mature deposits. Oligomers permeabilize membranes and disrupt multiple organelles, which is why lowering α-synuclein or blocking oligomer formation (not just clearing fibrils) is a therapeutic aim.
oligomers → protofibrils → mature fibrils → Lewy bodies — via characteristic histopathology — intraneuronal inclusions in dopaminergic neurons. Oligomers mature through protofibrils into insoluble amyloid fibrils that deposit as Lewy bodies and Lewy neurites — the pathological hallmark of Parkinson’s. Paradoxically, sequestration into Lewy bodies may be partly protective, removing the more toxic soluble oligomers from the cytosol.
misfolded α-synuclein (extracellular) → prion-like cell-to-cell templating — via Braak staging: olfactory bulb → brainstem → midbrain → cortex. Released misfolded α-synuclein is taken up by neighboring neurons, where it templates the misfolding of native protein — a prion-like, self-propagating spread. This mechanism explains the stereotyped, ascending progression of Lewy pathology described in Braak staging.
oligomers (intracellular) → mitochondrial dysfunction + ER stress + lysosomal failure — via complex I inhibition; UPR activation; chaperone-mediated autophagy disruption. Intracellular oligomers converge on several stress axes: they impair mitochondrial complex I, induce ER stress, and disrupt lysosomal/autophagic clearance (notably via GBA, the strongest common genetic risk factor). Impaired clearance then allows yet more α-synuclein to accumulate — a vicious cycle.
substantia nigra pars compacta neurons → progressive loss → striatal DA depletion — via motor symptoms manifest at ~50–70% neuronal loss (long preclinical phase). This toxicity is selective for the dopaminergic neurons of the substantia nigra pars compacta, whose progressive loss depletes striatal dopamine. Their high energy demand, pacemaking calcium load, and dopamine-derived oxidative stress may explain this particular vulnerability.
striatal DA depletion → motor symptoms (bradykinesia, rigidity, tremor) — via D1/D2 striatal output imbalance → indirect-pathway hyperactivity. Striatal dopamine depletion unbalances the basal-ganglia motor circuit, producing the cardinal motor signs — bradykinesia, rigidity, and resting tremor — once ~50-70% of nigral neurons are lost. Dopamine replacement (levodopa) treats these symptoms but does not slow the underlying aggregation.
Known Modulators
levodopa (substrate) — DA replacement (DOPA → DA via aromatic amino acid decarboxylase). Gold-standard symptomatic Rx; declining efficacy + motor fluctuations over years
selegiline (inhibitor) — MAO-B (DA preservation; possible neuroprotection)
rasagiline (inhibitor) — MAO-B (more selective than selegiline)
rapamycin (inhibitor) — mTORC1 → ↑autophagy clearance of α-synuclein (preclinical)